{"id":76362,"date":"2026-08-24T11:41:55","date_gmt":"2026-08-24T03:41:55","guid":{"rendered":"https:\/\/flcube.com\/?p=76362"},"modified":"2026-08-24T11:41:56","modified_gmt":"2026-08-24T03:41:56","slug":"simcere-h1-earnings-surge-as-neuroscience-revenue-jumps-60-9-and-profit-rises-37-9","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=76362","title":{"rendered":"Simcere H1 Earnings Surge as Neuroscience Revenue Jumps 60.9% and Profit Rises 37.9%"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Simcere Pharmaceutical<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/2096:HKG\">HKG: 2096<\/a>) released its interim results for the first half of 2026, reporting <strong>total revenue of RMB 4.58 billion<\/strong>, up <strong>27.8% year-on-year<\/strong>, and <strong>profit attributable to equity shareholders of RMB 829 million<\/strong>, up <strong>37.9% YoY<\/strong>, powered by its innovative drug franchise led by the neuroscience segment.<\/p>\n\n\n\n<h2 id=\"h-financial-highlights\" class=\"wp-block-heading\">Financial Highlights<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>H1 2026<\/th><th>YoY Change<\/th><\/tr><\/thead><tbody><tr><td><strong>Total Revenue<\/strong><\/td><td>RMB 4.58 bn<\/td><td><strong>+27.8%<\/strong><\/td><\/tr><tr><td><strong>Innovative Drug Revenue<\/strong><\/td><td>RMB 3.887 bn<\/td><td><strong>+34.1%<\/strong><\/td><\/tr><tr><td><strong>Innovative Drugs as % of Total<\/strong><\/td><td>84.9%<\/td><td>\u2013<\/td><\/tr><tr><td><strong>Profit Attributable to Shareholders<\/strong><\/td><td>RMB 829 m<\/td><td><strong>+37.9%<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-segment-performance-neuroscience-drives-growth\" class=\"wp-block-heading\">Segment Performance \u2013 Neuroscience Drives Growth<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Revenue was primarily derived from the Group&#8217;s core focus therapeutic areas:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Therapeutic Area<\/th><th>H1 2026 Revenue<\/th><th>% of Total<\/th><th>YoY Change<\/th><\/tr><\/thead><tbody><tr><td><strong>Neuroscience<\/strong><\/td><td>RMB 2.009 bn<\/td><td>43.9%<\/td><td><strong>+60.9%<\/strong><\/td><\/tr><tr><td><strong>Autoimmune Diseases<\/strong><\/td><td>RMB 1.210 bn<\/td><td>26.4%<\/td><td><strong>+37.8%<\/strong><\/td><\/tr><tr><td><strong>Oncology<\/strong><\/td><td>RMB 925 m<\/td><td>20.2%<\/td><td>+5.8%<\/td><\/tr><tr><td><strong>Other Sectors<\/strong><\/td><td>RMB 436 m<\/td><td>9.5%<\/td><td>\u221225.2%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-innovative-pipeline-amp-market-access\" class=\"wp-block-heading\">Innovative Pipeline &amp; Market Access<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Approved Portfolio:<\/strong> <strong>10 innovative drugs<\/strong> approved for marketing across neuroscience, oncology, autoimmune and anti-infection therapeutic fields<\/li>\n\n\n\n<li><strong>Clinical Recognition:<\/strong> As of June 30, 2026, multiple Group products are included in guidelines and clinical pathways issued by <strong>over 100 government authorities and leading professional societies<\/strong><\/li>\n\n\n\n<li><strong>Reimbursement Coverage:<\/strong> <strong>More than 45 products<\/strong> covered by the <strong>National Reimbursement Drug List (NRDL)<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-global-licensing-usd-4-6-billion-deal-pipeline\" class=\"wp-block-heading\">Global Licensing \u2013 USD 4.6 Billion Deal Pipeline<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Simcere has entered into out-licensing agreements with leading global pharmaceutical companies for <strong>five internally developed innovative drugs<\/strong>:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Partner<\/th><th>Status<\/th><\/tr><\/thead><tbody><tr><td><strong>AbbVie<\/strong><\/td><td>Out-licensing agreement<\/td><\/tr><tr><td><strong>Boehringer Ingelheim<\/strong><\/td><td>Out-licensing agreement<\/td><\/tr><tr><td><strong>Ipsen<\/strong><\/td><td>Out-licensing agreement<\/td><\/tr><tr><td><strong>Cumulative Transaction Value<\/strong><\/td><td><strong>&gt; USD 4.6 billion<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Innovation-Driven Mix:<\/strong> With innovative drugs generating 84.9% of revenue and growing 34.1% \u2014 ahead of overall growth \u2014 Simcere&#8217;s transition from generic-centric to innovation-centric revenue is now firmly entrenched.<\/li>\n\n\n\n<li><strong>Neuroscience as Flagship:<\/strong> Neuroscience overtook all other segments at 43.9% of revenue on 60.9% growth, making it the primary earnings engine and a differentiated strength in a therapeutic area few Chinese peers dominate.<\/li>\n\n\n\n<li><strong>Global Validation via Licensing:<\/strong> Cumulative out-licensing deals exceeding USD 4.6 billion with AbbVie, Boehringer Ingelheim and Ipsen provide external validation of Simcere&#8217;s R&amp;D quality and a source of milestone income largely insulated from domestic pricing pressure.<\/li>\n\n\n\n<li><strong>Structural Support:<\/strong> Coverage of 45+ products by the NRDL and inclusion in 100+ clinical guidelines support durable volume, even amid China&#8217;s ongoing drug price normalization.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Simcere Pharmaceutical&#8217;s revenue growth, product adoption and licensing milestones. Actual results may differ due to risks including NRDL pricing adjustments, clinical uptake, deal execution and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026082001846_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026082001846_c.\"><\/object><a id=\"wp-block-file--media-fa0e0030-f878-4533-9d11-67b605ebf4bb\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026082001846_c.pdf\">2026082001846_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026082001846_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-fa0e0030-f878-4533-9d11-67b605ebf4bb\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Simcere Pharmaceutical (HKG: 2096) released its interim results for the first half of 2026, reporting&#8230;<\/p>\n","protected":false},"author":1,"featured_media":76364,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7],"tags":[27,1099,271],"class_list":["post-76362","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-finanical-reports","tag-hkg-2096","tag-simcere-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Simcere H1 Earnings Surge as Neuroscience Revenue Jumps 60.9% and Profit Rises 37.9% - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Simcere Pharmaceutical (HKG: 2096) released its interim results for the first half of 2026, reporting total revenue of RMB 4.58 billion, up 27.8% year-on-year, and profit attributable to equity shareholders of RMB 829 million, up 37.9% YoY, powered by its innovative drug franchise led by the neuroscience segment.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=76362\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Simcere H1 Earnings Surge as Neuroscience Revenue Jumps 60.9% and Profit Rises 37.9%\" \/>\n<meta property=\"og:description\" content=\"Simcere Pharmaceutical (HKG: 2096) released its interim results for the first half of 2026, reporting total revenue of RMB 4.58 billion, up 27.8% year-on-year, and profit attributable to equity shareholders of RMB 829 million, up 37.9% YoY, powered by its innovative drug franchise led by the neuroscience segment.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=76362\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-24T03:41:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-24T03:41:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2402.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76362#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76362\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Simcere H1 Earnings Surge as Neuroscience Revenue Jumps 60.9% and Profit Rises 37.9%\",\"datePublished\":\"2026-08-24T03:41:55+00:00\",\"dateModified\":\"2026-08-24T03:41:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76362\"},\"wordCount\":383,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76362#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2402.webp\",\"keywords\":[\"Finanical Reports\",\"HKG: 2096\",\"Simcere Pharmaceutical\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=76362#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76362\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=76362\",\"name\":\"Simcere H1 Earnings Surge as Neuroscience Revenue Jumps 60.9% and Profit Rises 37.9% - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76362#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76362#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2402.webp\",\"datePublished\":\"2026-08-24T03:41:55+00:00\",\"dateModified\":\"2026-08-24T03:41:56+00:00\",\"description\":\"Simcere Pharmaceutical (HKG: 2096) released its interim results for the first half of 2026, reporting total revenue of RMB 4.58 billion, up 27.8% year-on-year, and profit attributable to equity shareholders of RMB 829 million, up 37.9% YoY, powered by its innovative drug franchise led by the neuroscience segment.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76362#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=76362\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76362#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2402.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2402.webp\",\"width\":1080,\"height\":608,\"caption\":\"Simcere H1 Earnings Surge as Neuroscience Revenue Jumps 60.9% and Profit Rises 37.9%\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76362#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Simcere H1 Earnings Surge as Neuroscience Revenue Jumps 60.9% and Profit Rises 37.9%\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Simcere H1 Earnings Surge as Neuroscience Revenue Jumps 60.9% and Profit Rises 37.9% - Insight, China&#039;s Pharmaceutical Industry","description":"Simcere Pharmaceutical (HKG: 2096) released its interim results for the first half of 2026, reporting total revenue of RMB 4.58 billion, up 27.8% year-on-year, and profit attributable to equity shareholders of RMB 829 million, up 37.9% YoY, powered by its innovative drug franchise led by the neuroscience segment.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=76362","og_locale":"en_US","og_type":"article","og_title":"Simcere H1 Earnings Surge as Neuroscience Revenue Jumps 60.9% and Profit Rises 37.9%","og_description":"Simcere Pharmaceutical (HKG: 2096) released its interim results for the first half of 2026, reporting total revenue of RMB 4.58 billion, up 27.8% year-on-year, and profit attributable to equity shareholders of RMB 829 million, up 37.9% YoY, powered by its innovative drug franchise led by the neuroscience segment.","og_url":"https:\/\/flcube.com\/?p=76362","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-24T03:41:55+00:00","article_modified_time":"2026-08-24T03:41:56+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2402.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=76362#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=76362"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Simcere H1 Earnings Surge as Neuroscience Revenue Jumps 60.9% and Profit Rises 37.9%","datePublished":"2026-08-24T03:41:55+00:00","dateModified":"2026-08-24T03:41:56+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=76362"},"wordCount":383,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=76362#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2402.webp","keywords":["Finanical Reports","HKG: 2096","Simcere Pharmaceutical"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=76362#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=76362","url":"https:\/\/flcube.com\/?p=76362","name":"Simcere H1 Earnings Surge as Neuroscience Revenue Jumps 60.9% and Profit Rises 37.9% - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=76362#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=76362#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2402.webp","datePublished":"2026-08-24T03:41:55+00:00","dateModified":"2026-08-24T03:41:56+00:00","description":"Simcere Pharmaceutical (HKG: 2096) released its interim results for the first half of 2026, reporting total revenue of RMB 4.58 billion, up 27.8% year-on-year, and profit attributable to equity shareholders of RMB 829 million, up 37.9% YoY, powered by its innovative drug franchise led by the neuroscience segment.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=76362#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=76362"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=76362#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2402.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2402.webp","width":1080,"height":608,"caption":"Simcere H1 Earnings Surge as Neuroscience Revenue Jumps 60.9% and Profit Rises 37.9%"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=76362#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Simcere H1 Earnings Surge as Neuroscience Revenue Jumps 60.9% and Profit Rises 37.9%"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2402.webp","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76362","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=76362"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76362\/revisions"}],"predecessor-version":[{"id":76365,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76362\/revisions\/76365"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/76364"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=76362"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=76362"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=76362"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}